Low doses of psilocybin (0.5 to 4.0 mg) produce perceptible pharmacological effects without causing hallucinations, cognitive impairment, or increased anxiety. In a Phase 1 randomized, double-blind, placebo-controlled trial, 56 healthy adults received a single oral dose of psilocybin or placebo. No serious adverse events occurred; side effects were comparable to placebo, mainly somnolence. Psilocin appeared rapidly in the blood with dose-proportional exposure and a short half-life. Subjective drug effects were dose-related and distinguishable from placebo at or below 2.5 mg, but hallucination and altered-states scores remained low and not different from placebo.
Religious and spiritual practices engage brain networks that regulate self-referential processing, salience, executive control, reward, and social bonding, as shown by functional neuroanatomy and network studies. These states are biochemically mediated by serotonin, dopamine, endogenous opioids, and oxytocin. Health benefits include reduced stress and inflammatory biomarkers. Positive religious/spiritual engagement and spiritually integrated psychotherapy are linked to lower depression and anxiety, while religious struggles predict worse outcomes. Resting posterior alpha activity may be a trait marker of resilience. Psychedelic-assisted therapy offers an opportunity to explore how network plasticity and mystical experiences can mediate durable clinical benefits, supporting an integrative mental healthcare approach.